Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.
He K, Puebla-Osorio N, Barsoumian HB, Sezen D, Rafiq Z, Riad TS, Hu Y, Huang A, Voss TA, Leyton CSK, Schuda LJ, Hsu E, Heiber J, Cortez MA, Welsh JW. He K, et al. Among authors: leyton csk. J Exp Clin Cancer Res. 2024 Sep 2;43(1):251. doi: 10.1186/s13046-024-03165-x. J Exp Clin Cancer Res. 2024. PMID: 39218928 Free PMC article.
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model.
Hu Y, Paris S, Bertolet G, Barsoumian HB, Wang Q, Da Silva J, Patel NB, Nguyen N, Doss DJ, Huang A, Hsu E, Leyton CSK, Voss TA, Masrorpour F, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Hu Y, et al. Among authors: leyton csk. Front Immunol. 2022 Nov 3;13:1022011. doi: 10.3389/fimmu.2022.1022011. eCollection 2022. Front Immunol. 2022. PMID: 36405757 Free PMC article.
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection.
Hu Y, Paris S, Sahoo N, Bertolet G, Wang Q, Wang Q, Barsoumian HB, Da Silva J, Huang A, Doss DJ, Pollock DP, Hsu E, Selene N, Leyton CSK, Voss TA, Masrorpour F, Ganjoo S, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Hu Y, et al. Among authors: leyton csk. JCI Insight. 2023 Jun 22;8(12):e167749. doi: 10.1172/jci.insight.167749. JCI Insight. 2023. PMID: 37345658 Free PMC article.
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
Hu Y, Revenko A, Barsoumian H, Bertolet G, Fowlkes NW, Maazi H, Green MM, He K, Sezen D, Voss TA, Leyton CSK, Masrorpour F, Rafiq Z, Puebla-Osorio N, Leuschner C, MacLeod R, Cortez MA, Welsh JW. Hu Y, et al. Among authors: leyton csk. J Exp Clin Cancer Res. 2024 Mar 6;43(1):70. doi: 10.1186/s13046-024-02992-2. J Exp Clin Cancer Res. 2024. PMID: 38443968 Free PMC article.
Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3.
Hu Y, Paris S, Sahoo N, Wang Q, Wang Q, Barsoumian HB, Huang A, Da Silva J, Bienassis C, Leyton CSK, Voss TA, Masrorpour F, Riad T, Leuschner C, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Hu Y, et al. Among authors: leyton csk. J Nanobiotechnology. 2024 Oct 1;22(1):597. doi: 10.1186/s12951-024-02855-0. J Nanobiotechnology. 2024. PMID: 39354474 Free PMC article.